

Richard J. Fruncillo, M.D., Ph.D.
7 Lakeview Place
Newtown Square, PA 19073

CURRICULUM VITAE

EDUCATION

1983-1985 Mercy Catholic Medical Center, Darby, PA
Internal Medicine Residency

1982-1983 Thomas Jefferson University, Philadelphia, PA
Fellowship in Clinical Pharmacology

1980-1982 The Hahnemann Medical College, Philadelphia, PA
Ph.D., Pharmacology

1979-1980 The Hahnemann Medical College Hospital, Philadelphia, PA
Family Medicine Internship

1975-1979 The Hahnemann Medical College, Philadelphia, PA
M.D.

1971-1975 The University of Pennsylvania, Philadelphia, PA
B.A., Chemistry

LICENSES Active Pennsylvania Medical License

SPECIALTY BOARD CERTIFICATION

2010 Certified, American Board of Toxicology (DABT)

1991 Certified, American Board of Clinical Pharmacology

1985 Certified, American Board of Internal Medicine

PROFESSIONAL EXPERIENCE

1985-present Independent consultant in toxicology, pharmacology, and
pharmacokinetics

2009-present Senior Director, Early Phase Research (part-time)
CRI Worldwide
16000 Horizon Way, Suite 100
Mt. Laurel, New Jersey 08054
856-533-5020

1996 - 2009 Senior Director, Clinical Research and Development
Clinical Pharmacology Unit - Wyeth Research
1300 Wolf Street
Philadelphia, PA 19148

PROFESSIONAL EXPERIENCE (cont.)

1985-present Expert witness consultant to plaintiff and defendant law firms in areas of Clinical Pharmacology and Toxicology (610-368-7201)

Some representative case examples are:

- phenol, TCE, benzene, mercury, nickel, toxicity
- Wrongful death from narcotic overdose
- Pain management malpractice
- Warfarin drug interactions
- Corticosteroid toxicity
- Blood alcohol concentration – effect relationships
- Post-mortem drug level interpretations
- Wrongful death from antidepressant overdose
- Local anesthetic toxicity
- Sedative toxicity
- Lithium drug interactions
- Non-steroidal anti-inflammatory drug toxicity
- Antibiotic toxicity
- Off label drug use
- Heparin toxicity
- Cardiovascular drug toxicity
- Antipsychotic toxicity
- Serotonin syndrome

1990 - 1995 Director, Clinical Pharmacology Unit
Wyeth-Ayerst Research
1300 Wolf Street
Philadelphia, PA 19148

1986-1990 Medical Consultant
Clinical Pharmacology Unit
Thomas Jefferson University
Philadelphia, PA

1986-1990 Staff Internist
Health Center System
City of Philadelphia

1986-1990 Instructor in Pharmacology
Department of Pharmacology
Thomas Jefferson University
Philadelphia, PA

1985-1986 Instructor in Pharmacology
Department of Pharmacology and Toxicology
Hahnemann University
Philadelphia, PA

ACADEMIC AFFILIATIONS

1990-1995 Adjunct Assistant Professor of Medicine
University of Pennsylvania
School of Medicine
Philadelphia, PA

COMMITTEE MEMBERSHIPS

- 1987-1990 Pharmacy and Therapeutics Committee
City of Philadelphia Department of Public Health
Philadelphia, PA
- 1990-1995 Pharmacy and Therapeutics Committee
The Graduate Hospital
Philadelphia, PA

RESEARCH EXPERIENCE

- 1990-2009 Clinical Pharmacology Unit of Wyeth-Ayerst Research
Principal Investigator for 12-16 Phase I studies each year.
- 1982-1990 Jefferson Medical College
Research involving various hypertensive and pharmacokinetic protocols in humans and laboratory animals.
- 1980-1982 The Hahnemann Graduate School
Continuing research on mechanism of drug metabolism depression in burns: other projects include pharmacokinetics of theophylline in biliary stasis; interaction of cimetidine with lidocaine and quinidine; pharmacokinetics of theophylline in burn patients; pharmacokinetics of pentobarbital, theophylline quinidine and lidocaine in burned rats; protein binding of drugs in burned rats and humans.
- 1975-1979 The Hahnemann Medical College
Research and published (see Publications) in the fields of human and animal drug metabolism, specifically drug metabolism in burns and other inflammatory conditions.
- 1971-1975 The University of Pennsylvania
During my four summer vacations, I worked with three different professors in the fields of organic and inorganic chemistry on such projects as photochemistry of pinacols, Wolff rearrangement II, and production of silicon for solar cells from silicon tetrafluoride gas.

TEACHING EXPERIENCE

- 1986-1990 Lectures to fourth year medical students in Clinical Pharmacology
- 1983-1986 Involved in various aspects of medical and graduate student training.
- 1982-1983 Lectures to fourth year medical students in Clinical Pharmacology.
- 1980-1982 Lectures to third year medical students in Clinical Therapeutics.
- 1980-1982 Member of Clinical Pharmacology Consulting Service for hospitalized patients with drug-related problems.

TEACHING EXPERIENCE (cont.)

- 1980-1982 Formal conferences to medical and pediatric residents in the area of Clinical Pharmacology.
- 1980-1982 Formal Lectures in Medical Pharmacology course for Physician's Assistants and Respiratory Therapists.
- 1980-1982 Conducted conference and laboratory sessions for Medical pharmacology course for first year medical students.
- 1979-1980 Involved in various aspects of medical student teaching while medical intern.
- Summer, 1974 Taught a ten-student laboratory section of Organic Chemistry Laboratory I, University of Pennsylvania.
- 1971-1975 As Vice President of the University of Pennsylvania's ACS Student Affiliates, I conducted many conferences and review sessions for freshman chemistry and nursing students in the field of general in organic chemistry.

EXTRA-INSTITUTIONAL ACTIVITIES

- 1985 Member of Multidisciplinary Pain Management Team, Hahnemann Univ.
- 1980-1981 Employed with Western Consulting Company to give introductory toxicology lectures as part of a toxic waste disposal course for industrial scientists and technicians.
- 1980-2000 Part-time house physician in 200 bed community hospital with responsibility for medical-surgical, cardiac and intensive care patients.

HONORS

- 1974 Phi Beta Kappa, University of Pennsylvania
- 1972 Chemical Rubber Company Chemistry Award
University of Pennsylvania
- 1973 Hiram Lukens Chemistry Scholarship
University of Pennsylvania
- 1975 American Chemical Society Chemistry Award
University of Pennsylvania
- 1975 Epsilon Delta Premedical Honorary Society
University of Pennsylvania
- 1975 Upsilon Chemistry Honorary Society
University of Pennsylvania

HONORS (cont.)

1975	Summa Cum Laude University of Pennsylvania
1976	Letter of Commendation in Pharmacology Hahnemann Medical College
1978	Commendation in Gastroenterology Hahnemann Medical College
1978	Letter of Commendation in Nephrology Hahnemann Medical College
1979	Honors in Pharmacology Hahnemann Medical College
1979	Upjohn Research Award Hahnemann Medical College
1982	Charles E. Culpepper Foundation Fellowship Jefferson Medical College

MEMBERSHIPS

American College of Clinical Pharmacology

American Society for Clinical Pharmacology and Therapeutics

American Academy of Clinical Toxicology

American Mensa Association

Colloquy Society

SCIENTIFIC PUBLICATIONS

1. Ciaccio EI, Fruncillo RJ: Urinary excretion of D-glucaric acid by severely burned patients. Clin Pharmacol Ther 25:340-344, 1979
2. Ciaccio EI, Fruncillo RJ: Decreased aryl hydrocarbon hydroxylase after a 15% burn injury. Biochem Pharmacol 28:3151-3152, 1979.
3. Fruncillo RJ, Gibbons W, Bowman SM: CNS toxicity after ingestion of topical lidocaine. N. Engl J Med 306:426-427, 1982
4. Durlofsky L, Fruncillo RJ: Impaired drug metabolizing ability in the burned rat. Journal of Trauma 22:950-953, 1982.
5. Fruncillo RJ, DiAngelis P, DiGregorio GJ: Pharmacokinetics of Theophylline in rats with biliary stasis. J Pharm Pharmacol 34:741-743, 1983.

6. Fruncillo RJ, DiGregorio GJ, Soll A: Effect of cimetidine on the pharmacokinetics of quinidine and lidocaine in the rat. *J Pharm Sci* 72:826-828, 1983.
7. Fruncillo RJ, DiGregorio GJ: The effect of thermal injury on drug metabolism in the rat. *Journal of Trauma* 23:523-529, 1983.
8. DiGregorio GJ, Fruncillo RJ: Antiemetic drugs. *Am Fam Phys* 26:200-202, 1982.
9. Fruncillo RJ, DiGregorio GJ: The pharmacokinetics of pentobarbital, quinidine, lidocaine and theophylline in the thermally-injured rat. *Journal of Pharm Sci* 73:1117-1119, 1984.
10. Fruncillo RJ, Antipsychotic drugs. Published as a chapter in a handbook by Hoffman LaRoche, 1983.
11. Fruncillo RJ: Drug disposition in liver disease. *Am Fam Phys* 26:167-169, 1982.
12. DiGregorio GJ, Fruncillo RJ: Drug Overdose. In: Miller HA, Major DA and Oaks WW (eds), *ICU Medicine: Grune and Stratton, New York, 1983, pp. 85-88.*
13. Fruncillo RJ, Rotmensch HH, Vlasses PH, Kopkin JR, Ferguson RK: Effects of captopril and hydrochlorothiazide on the pressor response to norepinephrine and angiotensin II in hypertensive patients. *Eur J Clin Pharmacol* 28:5-9, 1985.
14. Fruncillo RJ: Clinical toxicology of polychlorinated biphenyls (PCB's). *Am Fam Phys* 31:202-205, 1985.
15. Fruncillo RJ, Gibbons WJ, Vlasses PH, Ferguson RK: Severe hypotension associated with concurrent clonidine and antipsychotic medication.
16. Rocci ML, Grasela D, Fruncillo RJ, Vlasses PH: The effects of single doses of cimetidine on estimated hepatic blood flow. *Drug Intell Clin Pharm* 19:831-834, 1985.
17. Fruncillo RJ, Swanson BN, Bernhard R, Marchion C, Ferguson RK: Effect of renal failure or biliary stasis on the pharmacokinetics of amiodarone in the rat. *J Pharm Sci* 75:150-154, 1986.
18. Fruncillo, RJ, Bernhard R, Swanson, BN, Vlasses PH, Ferguson RK: Effect of phenobarbital on the pharmacokinetics and tissue levels of amiodarone in the rat. *J Pharm Pharmacol* 37:729-731, 1985.
19. Vlasses PH, Conner DP, Rotmensch HH, Fruncillo RJ, Danzeisen JR, Shepley KJ, Ferguson RK: Double-blind comparison of captopril and enalapril in mild to moderate hypertension. *J Am Coll Cardiol* 7:651-660, 1986.
20. Fruncillo RJ, Rocci ML, Vlasses PH, Mojaverian P, Shepley K, Clementi R, Oren A, Smith R, Till AE, Riley LJ, Krishna G, Narins RG, Ferguson RK: Disposition of enalapril and enalaprilat in renal insufficiency. *Kid Int* 31:Suppl. 20:117-122, 1986.
21. Fruncillo RJ: Management of Pain, in *Handbook of Pain Management*. DiGregorio, GJ, (Ed.) Medical Surveillance, Inc., West Chester, PA, 1986.

22. Fruncillo RJ, Ruch E, DiGregorio GH: The Effect of Acute Hepatic Injury on the Disposition of Vitamin A in the Rat. *Res Comm Chem Path Pharm* 54:283-286, 1986.
23. Fruncillo RJ: Toxin induced Parkinson's disease - recent developments. *Am Fam Phys* 33:251-254, 1986.
24. Fruncillo RJ, Kozin S, DiGregorio GJ: Effect of amiodarone on the pharmacokinetics of phenytoin, quinidine and lidocaine in the rat. *Res Comm Chem Path Pharm*, 50:451-454, 1985.
25. Fruncillo RJ: Drug Therapy in the Elderly. *Am Fam Phys* 35:225-228, 1987.
26. Rocci ML, Vlases PH, Lener ME, Fruncillo RJ, Sirgo MA: Comparative Evaluation of the effects of labetalol, verapamil and diltiazem on antipyrine and Indocyanine Green Clearances. *J Clin Pharmacol* 29:891-895, 1989.
27. McCrea JB, Fruncillo RJ, Holland SD, Conroy JA, Shingo S, Spector R, Bjornsson TD: Lovastatin does not affect oral glucose tolerance in hypercholesterolemic patients. *J Clin Pharmacol* 33 (6). 1993. 581-585.
28. Troy SM, Parker VD, Fruncillo RJ, Chiang, ST: The pharmacokinetics of Venlafaxine when given in a twice daily regimen. *J. Clin Pharmacol* 35:404-409, 1995.
29. Fruncillo RJ, Troy SM, Parker VD, Mayersohn M, Hicks D, Kraml M, Battle M, Chiang ST: Pharmacokinetics of the aldose reductase inhibitor tolrestat: studies in healthy young and elderly male and female subjects and in subjects with diabetes. *Clin Pharm Ther*, 59:603, 1996.
30. Troy S, Fruncillo RJ, Ozawa T, Mammen E, Holloway S, Chiang S: The Dose Proportionality of the Pharmacokinetics of Ardeparin, a Low Molecular Weight Heparin, in healthy volunteers. *J Clin Pharmacol* 35:1194-1199, 1995
31. Troy S, Fruncillo R, Ozawa T, Mammen E, Holloway S, Chiang S: Absolute and comparative subcutaneous bioavailability of ardeparin sodium, a low molecular weight heparin. *Thromb Haemost*, 78:871, 1997.
32. Ermer JC, Boni JP, Cevallos WH, DeCleene S, Burghart P, Rudnick MR, Fruncillo RJ, Berns JS, Cohen RM: Bromfenac disposition in patients with impaired kidney function; *Clin Pharmacolo Ther*, 61:312, 1997.
33. Troy S, Dilea C, Martin P, Rosen A, Fruncillo R, Chiang S: Bioavailability of once-daily Venlafaxine Extended Release compared with the immediate-release formulation in healthy adult volunteers; *Current Therapeutic Res* 58:492, 1997.
34. Chiang ST, Fruncillo RJ, Ermer JC, Hicks D, Orczyk G, Klamerus K: Effects of age, gender and food on the pharmacokinetics of Etodolac Enantiomers after single and multiple doses of an extended release formulation. Submitted to *J. Clin Pharmacol*, 1998
35. Ferron GM, Paul J, Fruncillo RJ, Martin PT, Yacoub L, Mayer P: Lack of Pharmacokinetic Interaction between Oral Pantoprazole and Cisapride in Healthy Adults. *J. Clin Pharmacol*, 1999;39:945-950.

36. Danjou P, Paty I, Fruncillo RJ, Worthington P, Unruh M, Cevallos W, Martin P: A comparison of the residual effects of zoloplon and zolpidem following administration 5 to 2h before awakening. *Br J Clin Pharmacol*, 48, 367-374.
37. Ball SE, Scatina J, Kao J, Ferron G, Fruncillo RJ, Mayer P, Weinryb I, Guida M, Hopkins P, Warner N, Hall J: Population distribution and effects on drug metabolism of a genetic variant in the 5' promoter region of CYP3A4. *Clin Pharmacol Ther* 1999;66:288-94.
38. Ferron GM, Paul J, Fruncillo R, Richards L, Knebel N, Getsy J, Troy S: Multiple-dose, linear, dose-proportional pharmacokinetics of retigabine in healthy volunteers. *Journal of Clinical Pharmacology*. 42(2):175-82, 2002 Feb.
39. Yengi LG, Xiang Q, Pan J, Scatina J, Kao J, Ball SE, Fruncillo R, Ferron G, Roland Wolf C: Quantitation of cytochrome P450 mRNA levels in human skin. *Analytical Biochemistry*. 316(1):1-3-10, 2003 May1.
40. Muralidharan G, Fruncillo R, Micalizzi M, Raible DG, Troy SM: Effects of age and sex on single-dose pharmacokinetics of tigecycline in healthy subjects. *Antimicrobial Agents & Chemotherapy*. 49(4):1656-9, 2005 Apr.
41. Zimmerman JJ, Harper DM, Matschke K, Speth JL, Raible DG, Fruncillo RJ. Absence of an interaction between tigecycline and digoxin in healthy men. *Pharmacotherapy*, 27(6):835-44, 2007 Jun.
42. Fruncillo RJ, 1500 Review Questions in Toxicology. Submitted for publication, 2010.

ABSTRACTS

1. Fruncillo RJ, Rotmensch HH, Vlasses PH, Ferguson RK: Effect of captopril and hydrochlorothiazide on the pressor responses to norepinephrine and angiotensin II in hypertensive. *Clin Pharmacol Ther* 33:226, 1983.
2. Fruncillo RJ, DiGregorio, GJ: Depresses *in vivo* and *in vitro* hepatic drug metabolism in the thermally-injured rat. *Federation Proceedings* 42:912, 1983.
3. Ferguson RK, Rotmensch HH, Vlasses PH, Swanson BN, Fedder IL, Vincent ME, Fruncillo RJ: Hemodynamic effects of enalapril maleate in hypertensive patients. *Clin Res* 31:232, 1983.
4. Fruncillo RJ, Swanson BN, Bernhard R, Marchion C: Amiodarone pharmacokinetics in rats with renal failure and biliary stasis. *Pharmacologist* 25:232, 1983.
5. Fruncillo RJ, Bernhard R, Swanson BN, Vlasses PH, Ferguson RK: The effect of phenobarbital on the pharmacokinetics and tissue levels of amiodarone. *Clin Pharmacol Ther* 35:241, 1984.
6. Bernhard R, Fruncillo RJ, Swanson BN, Ferguson BK: The effect of 3-methylcholanthrene on the pharmacokinetics of amiodarone in the rat. *Federation Proceedings* 43:749, 1984.
7. Rocci Jr ML, Grasela DM, Fruncillo RJ, Rotmensch HH, Vlasses PH: Do H₂-receptor antagonists alter hepatic blood flow? *Clin Res* 32:247A, 1984.

8. Fruncillo RJ, Bernhard R, Rocci Jr ML, Ferguson RK: The biliary disposition of amiodarone in the rat: Evidence against enterohepatic recirculation. Clin Res 32:671A, 1984.
9. Vlasses PH, Conner DP, Rocci Jr ML, Rotmensch HH, Fruncillo RJ, Ferguson RK: Do captopril and enalapril differ in their antihypertensive mechanism? Clin Res 32:791A, 1984.
10. Fruncillo RJ, Rocci Jr ML, Shepley K, Clementi RA, DeRita R, Mojaverian P, Smith RD, Ferguson RK: Enalaprilat accumulates after chronic enalapril dosing in renal failure. Clin Pharmacol Ther 37:197, 1985.
11. Kozin S, Fruncillo RJ, DiGregorio GJ. Effect of Amiodarone on the pharmacokinetics of phenytoin, quinidine and lidocaine in the rat. Clin Res 34:316A, 1986.
12. Fruncillo RJ, Bernhard R, Ferguson RK: The effects of renal failure or biliary stasis on the tissue levels of amiodarone. Clin Pharmacol Ther 37:197, 1985.
13. Riley Jr. LJ, Fruncillo RJ, Smith RD, Vlasses PH, Conner DP, Narins RG, Mojaverian P, Krishna G, Till AE, Ferguson RK: Enalapril maleate in renal failure: relationships between blood pressure response aldosterone, and accumulation of active metabolite. Clin Res 33:368A, 1985
14. Riley LJ, Fruncillo RJ, Smith R, Vlasses PH, Conner DP, Narins RG, Mojaverian P, Krishna G, Till AE, Ferguson RK: The safety and antihypertensive effect of once daily enalapril maleate in renal failure. Clin Res 33:85A, 1985
15. Fruncillo RJ, DiGregorio GH, Ruch E, Kozin S, Lubniewski A: The effect of acute liver injury on the disposition of vitamin A in the rat. Clin Res 34:441A 1986.
16. Vlasses PH, Foley J, Fruncillo RJ, Nowacki J, Brennan J, Ivashkiv E, Tu J: Disposition and efficacy of repeated doses of zofenopril in mild to moderate hypertension. Clin Pharmacol Ther 47:173, 1990.
17. Korth-Bradley JM, Fruncillo RJ, Klamerus KJ, Chiang ST, Conrad KA: The influence of high and low fat meals on single dose pharmacokinetics of zalospirone. Pharm Res, NY9(10 Suppl) S326, 1992.
18. Fruncillo RJ, Troy SM, Parker V, Hicks D, Turner MB, Chiang ST: Effect of age and sex on tolrestat pharmacokinetics. Clin Pharm Ther 53:193, 1993.
19. Ben-Maimon C, Korth-Bradley JM, Cevallos W, Fruncillo RJ, Chiang ST. Stereospecific pharmacokinetics of pemedolac in healthy male volunteers. Clin Pharmacol Ther 53:223, 1993.
20. Ermer JC, Burghart P, Rudnick M, Cevallos W, Fruncillo RJ, Berns J, Cohen R, DeCleene S and Chiang ST. The effect of renal disease on bromfenac disposition. Pharm Res 10(10 Suppl), S105, 1993.

21. Garg V, Parker V, Turner MB, Burghart P, Fruncillo RJ, Battle M and Chaing ST: Pharmacokinetic interaction between aspirin and tolrestat in normal volunteers. *Pharm Res* (1994)
22. Epstein M, Orczyk G, Muralidharan G, Fruncillo RJ, VPA-985: a novel non-peptide competitive vasopressin receptor antagonist for the treatment of dilutional hyponatremia. *J Am. Soc. Nephrol* 1998;9:0544
23. Muralidharan G, Meng X, DeCleene SA, Cevallos WH, Fruncillo R, Hicks D, Orczyk GP. Pharmacokinetics and pharmacodynamics of a novel vasopressin receptor antagonist, VPA-985 in healthy subjects. *Clin Pharmacol Ther* 1999;65:189.
24. Klamerus KJ, Battle MM, Burghort BF, Whitehead DI, Neefe DL, Fruncillo RJ, Weinryb I and Mayer PR. Effects of concomitant tasesartan and HCTZ administration in healthy volunteers. *Am J JHypertans* (1997) 10, 118A
25. Zimmerman JJ, Harper D, Speth JT, Fruncillo RJ, Getsy J, eds, Potential pharmacokinetic interactions between sirolimus and atorvastatin [abstract]. *ESOT*. 2001;(Oct 6-11); 145
26. Darwish M, Parker V, Harper D, Leister C, Raible D, Fruncillo R. The lack of drug interactions between zaleplon and venlafaxine extended release. 155th Annual Meeting of the American Psychiatric Association, 2002.
27. Zimmerman JJ, Harper D, Matschke K, Speth J, Raible DC, Fruncillo RJ. Tigecycline (Tgc) and digoxin (Dig) co-administered to healthy men Abstract A-460 presented at: 44th Interscience Conference on Antimicrobial Agents and Chemotherapy: October 30 through November 2 2004: Washington DC.
28. Richards LS, Behrle JA, Nichols AI, Fruncillo RJ, Paul J. An ascending multiple dose study of the safety and pharmacokinetics of a sustained release formulation of desvenlafaxine succinate in healthy subjects. *Clin Pharmacol Ther* (2005) 77, P84
29. Parker VD, Richards, LS, Nichols AI, Behrle JA and Fruncillo R (2005) The absolute bioavailability of an oral sustained-release formulation of desvenlafaxine succinate in healthy subjects. In *Proceedings of the Annual Meeting of the American Society of Clinical Pharmacology and Therapeutics*: 2005 March 2-5; Orlando, FL. American Society for Clinical Pharmacology and Therapeutics, Alexandria, VA.

PRESENTATIONS

1. American Society for Clinical Pharmacology and Therapeutics, Spring 1983. Effects of captopril and hydrochlorothiazide on the responses to norepinephrine and angiotensin II in hypertensin.
2. Federation Meeting, Spring, 1983. Depressed *in vivo* and *in vitro* hepatic drug metabolism in the thermally injured rat.
3. American Society for Pharmacology and Experimental Therapeutics, Summer, 1983. Amiodarone pharmacokinetics in rats with renal failure and biliary stasis.
4. American Society for Clinical Pharmacology and Therapeutics, Spring, 1984. The effect of phenobarbital on the pharmacokinetics and tissue levels of amiodarone.

5. American Society of Clinical Pharmacology and Therapeutics, Spring, 1985. Enalaprilate accumulates after chronic enalapril dosing in renal failure.
6. American Society for Clinical Pharmacology and Therapeutics, Spring, 1985. The effect of renal failure or biliary stasis on the tissue levels of amiodarone.
7. American College of Clinical Pharmacology, Fall, 1985. Enalapril maleate in renal failure: relationship between blood pressure response, aldosterone, and accumulation of active metabolite.
8. American Society for Clinical Pharmacology and Therapeutics, Spring 1993. Effect of age and sex on tolrestat pharmacokinetics.
9. Pituitary Society, Fall 1998. The Pharmacodynamics of a Novel Vasopressin-2 Antagonist in Healthy Volunteers.